WG6. Clinical Trials
Leadership
Philippe Aftimos
INSTITUT BORDET
Elinor Sawyer
KING'S COLLEGE LONDON
Rachel Jankowitz
UNIVERSITY OF PENNSYLVANIA
Rian Terveer-Couperus
PA (NETHERLANDS)
Esther Geven
PA (NETHERLANDS)
Participants
| Patrick Derksen (UMC Utrecht) |
| Sabine Linn (NKI-AvL) |
| Agnes Jager (Erasmus MC) |
| Christine Desmedt (KU Leuven) |
| Chris Lord (NKI-AvL) |
| Jason Mouabbi (MD Anderson) |
| Adrian Lee (UPMC) |
| Rachel Natrajan (ICR London) |
| Georgios Sflomos (EFPL) |
| Marleen Kok (NKI-AvL) |
| Elzbieta Senkus (University of Gdansk) |
| Cathrin Brisken (EFPL and ICR London) |
| Philippe Aftimons (Institut Bordet) |
| Rachel Natrajan (ICR London) |
| Rita Mukhtar (UCSF) |
| Renee Flaherty (ICR London) |
| Marion Maetens (KU Leuven) |
Past and Future meetings
GLOBAL STRATEGY MEETING (APRIL 16th 2024) LONDON)
Meeting at Guy’s Hospital in London. Hosted by Elly Sawyer. Discussions on ILC specific intervention options
LOBULAR BASKET TRIAL MEETING (OCTOBER 14th 2022) LONDON)
First clinical WG meeting at Guy’s Hospital in London. Hosted by Elly Sawyer. Discussions on ILC specific intervention options
Activities
The Clinical working group has been meeting on a regular basis and has played an important role in the start of the first ILC specific trials such as RoLo, ROSALINE, and the current developments in the context of AKT inhibition using Capivasertib.
A very comprehensive overview of the recent and ongoing ILC trials was published in 2024 by groups of the ELBCC headed by KU Leuven:
